Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatiti
Go back to Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatiti| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1152.44 +14.62 (1.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1137.82 | 52 Week High | $88.16 | |||
| Open | $1150.27 | 52 Week Low | $67.88 | |||
| Day High | $1159.75 | P/E | 266.77 | |||
| Day Low | $1138.26 | EPS | $4.32 | |||
| Volume | 1,897,937 | |||||
